Credit: Calliditas. The conversion to regular approval was based on data from an additional 165 patients with biopsy-proven IgAN in the phase 3 NeflgArd trial. The conversion to regular approval was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback